Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate
composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a …

Simple Summary Novel anti-HER2 antibody–drug conjugates showed convincing efficacy in
HER2-Low breast cancer patients. We aimed to investigate the accuracy of core needle …

Simple Summary The development of new strategies for the management of cutaneous
metastases is a major clinical challenge because of the poor prognosis. To advance in this …

Introduction HER2‐low breast cancer is a gradually recognized and unexplored group of
diseases. We aimed to investigate the clinical and prognosis features and to identify the role …

Objective To evaluate and validate the recent and emerging data for prognostic and
predictive biomarkers with therapeutic targets in breast cancer. Data sources A literature …

Background Triple negative breast cancer (TNBC) is characterized by high rates of
recurrence, especially in patients with residual disease after neoadjuvant chemotherapy …

Emerging data suggests that HER2 intratumoral heterogeneity (ITH) is associated with
therapy resistance, highlighting the need for new strategies to assess HER2 ITH. A …

Background Breast cancer with fluorescence in situ hybridization (FISH) group 2 pattern
(HER2< 4 and HER2/CEP17 ratio≥ 2, a subset of monosomy CEP17) was historically …

Purpose HER2 overexpression and gene amplification are routinely tested by
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively. In …

Breast cancer is a significant global health concern, with the overexpression of human
epidermal growth factor receptor 2 (HER2/ERBB2) being a driver oncogene in 20%–30% of …